These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 27558654

  • 1. Oral iron supplementation with sodium ferrous citrate reduces the serum intact and c-terminal fibroblast growth factor 23 levels of maintenance haemodialysis patients.
    Yamashita K, Mizuiri S, Nishizawa Y, Kenichiro S, Doi S, Masaki T.
    Nephrology (Carlton); 2017 Dec; 22(12):947-953. PubMed ID: 27558654
    [Abstract] [Full Text] [Related]

  • 2. Oral Versus Intravenous Iron Supplementation for the Treatment of Iron Deficiency Anemia in Patients on Maintenance Hemodialysis-Effect on Fibroblast Growth Factor-23 Metabolism.
    Fukao W, Hasuike Y, Yamakawa T, Toyoda K, Aichi M, Masachika S, Kantou M, Takahishi SI, Iwasaki T, Yahiro M, Nanami M, Nagasawa Y, Kuragano T, Nakanishi T.
    J Ren Nutr; 2018 Jul; 28(4):270-277. PubMed ID: 29703633
    [Abstract] [Full Text] [Related]

  • 3. Phosphate control in reducing FGF23 levels in hemodialysis patients.
    Rodelo-Haad C, Rodríguez-Ortiz ME, Martin-Malo A, Pendon-Ruiz de Mier MV, Agüera ML, Muñoz-Castañeda JR, Soriano S, Caravaca F, Alvarez-Lara MA, Felsenfeld A, Aljama P, Rodriguez M.
    PLoS One; 2018 Jul; 13(8):e0201537. PubMed ID: 30086150
    [Abstract] [Full Text] [Related]

  • 4. Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial.
    Roberts MA, Huang L, Lee D, MacGinley R, Troster SM, Kent AB, Bansal SS, Macdougall IC, McMahon LP.
    BMC Nephrol; 2016 Nov 16; 17(1):177. PubMed ID: 27852236
    [Abstract] [Full Text] [Related]

  • 5. Parenteral iron polymaltose changes i:c-terminal FGF23 ratios in iron deficiency, but not in dialysis patients.
    Tan SJ, Satake S, Smith ER, Toussaint ND, Hewitson TD, Holt SG.
    Eur J Clin Nutr; 2017 Feb 16; 71(2):180-184. PubMed ID: 27848940
    [Abstract] [Full Text] [Related]

  • 6. Administration of Ferric Citrate Hydrate Decreases Circulating FGF23 Levels Independently of Serum Phosphate Levels in Hemodialysis Patients with Iron Deficiency.
    Iguchi A, Kazama JJ, Yamamoto S, Yoshita K, Watanabe Y, Iino N, Narita I.
    Nephron; 2015 Feb 16; 131(3):161-6. PubMed ID: 26551233
    [Abstract] [Full Text] [Related]

  • 7. Alterations in regulators of the renal-bone axis, inflammation and iron status in older people with early renal impairment and the effect of vitamin D supplementation.
    Christodoulou M, Aspray TJ, Piec I, Fraser WD, Schoenmakers I, VDOP Trial group.
    Age Ageing; 2024 May 01; 53(5):. PubMed ID: 38770543
    [Abstract] [Full Text] [Related]

  • 8. Plasma fibroblast growth factor 23 concentration and iron status. Does the relationship exist in the elderly population?
    Bożentowicz-Wikarek M, Kocełak P, Owczarek A, Olszanecka-Glinianowicz M, Mossakowska M, Skalska A, Więcek A, Chudek J.
    Clin Biochem; 2015 Apr 01; 48(6):431-6. PubMed ID: 25583093
    [Abstract] [Full Text] [Related]

  • 9. Relation between Red Cell Distribution Width and Fibroblast Growth Factor 23 Cleaving in Patients with Chronic Kidney Disease and Heart Failure.
    van Breda F, Emans ME, van der Putten K, Braam B, van Ittersum FJ, Kraaijenhagen RJ, de Borst MH, Vervloet M, Gaillard CA.
    PLoS One; 2015 Apr 01; 10(6):e0128994. PubMed ID: 26079688
    [Abstract] [Full Text] [Related]

  • 10. Low serum iron is associated with high serum intact FGF23 in elderly men: The Swedish MrOS study.
    Lewerin C, Ljunggren Ö, Nilsson-Ehle H, Karlsson MK, Herlitz H, Lorentzon M, Ohlsson C, Mellström D.
    Bone; 2017 May 01; 98():1-8. PubMed ID: 28212898
    [Abstract] [Full Text] [Related]

  • 11. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.
    Wolf M, Koch TA, Bregman DB.
    J Bone Miner Res; 2013 Aug 01; 28(8):1793-803. PubMed ID: 23505057
    [Abstract] [Full Text] [Related]

  • 12. Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses.
    Block GA, Pergola PE, Fishbane S, Martins JG, LeWinter RD, Uhlig K, Neylan JF, Chertow GM.
    Nephrol Dial Transplant; 2019 Jul 01; 34(7):1115-1124. PubMed ID: 30380116
    [Abstract] [Full Text] [Related]

  • 13. Strength of Fibroblast Growth Factor 23 as a Cardiovascular Risk Predictor in Chronic Kidney Disease Weaken by ProBNP Adjustment.
    Emrich IE, Brandenburg V, Sellier AB, Schauerte J, Wiedenroth J, Untersteller K, Lennartz CS, Seiler-Mussler S, Wagenpfeil S, Fliser D, Heine GH.
    Am J Nephrol; 2019 Jul 01; 49(3):203-211. PubMed ID: 30808827
    [Abstract] [Full Text] [Related]

  • 14. Associations Between Intravenous Iron, Inflammation and FGF23 in Non-Dialysis Patients with Chronic Kidney Disease Stages 3-5.
    Muras-Szwedziak K, Nowicki M.
    Kidney Blood Press Res; 2018 Jul 01; 43(1):143-151. PubMed ID: 29444509
    [Abstract] [Full Text] [Related]

  • 15. Fibroblast growth factor 23 (FGF23) and early chronic kidney disease in the elderly.
    Chudek J, Kocełak P, Owczarek A, Bożentowicz-Wikarek M, Mossakowska M, Olszanecka-Glinianowicz M, Wiecek A.
    Nephrol Dial Transplant; 2014 Sep 01; 29(9):1757-63. PubMed ID: 24729016
    [Abstract] [Full Text] [Related]

  • 16. Saccharated ferric oxide attenuates haematopoietic response induced by epoetin beta pegol in patients undergoing haemodialysis.
    Iwasaki T, Fujimori A, Nakanishi T, Okada S, Hanawa N, Hasuike Y, Kuragano T.
    BMC Nephrol; 2021 Apr 08; 22(1):124. PubMed ID: 33832448
    [Abstract] [Full Text] [Related]

  • 17. Lower serum fibroblast growth factor-23 levels may suggest malnutrition in maintenance haemodialysis patients.
    Mizuiri S, Nishizawa Y, Yamashita K, Ono K, Oda M, Usui K, Shigemoto K.
    Nephrology (Carlton); 2014 Sep 08; 19(9):568-73. PubMed ID: 24947687
    [Abstract] [Full Text] [Related]

  • 18. Effect of ferric citrate hydrate on fibroblast growth factor 23 and platelets in non-dialysis-dependent chronic kidney disease and non-chronic kidney disease patients with iron deficiency anemia.
    Ito K, Akizawa T, Arita K, Mitobe Y, Komatsu N.
    Clin Exp Nephrol; 2024 Jul 08; 28(7):636-646. PubMed ID: 38402503
    [Abstract] [Full Text] [Related]

  • 19. Effect of Ferric Citrate versus Ferrous Sulfate on Iron and Phosphate Parameters in Patients with Iron Deficiency and CKD: A Randomized Trial.
    Womack R, Berru F, Panwar B, Gutiérrez OM.
    Clin J Am Soc Nephrol; 2020 Sep 07; 15(9):1251-1258. PubMed ID: 32694162
    [Abstract] [Full Text] [Related]

  • 20. Effect of ferric citrate hydrate on FGF23 and PTH levels in patients with non-dialysis-dependent chronic kidney disease with normophosphatemia and iron deficiency.
    Iguchi A, Yamamoto S, Yamazaki M, Tasaki K, Suzuki Y, Kazama JJ, Narita I.
    Clin Exp Nephrol; 2018 Aug 07; 22(4):789-796. PubMed ID: 29181658
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.